Brazilian initial experience with lung transplantation due to irreversible lung fibrosis post-COVID-19 in a national reference center: a cohort study
Authors:
- Flavio Pola dos ReisFRFlavio Pola dos Reis
- Lucas Matos FernandesLFLucas Matos Fernandes
- Luis Gustavo AbdallaLALuis Gustavo Abdalla
- Silvia Vidal CamposSCSilvia Vidal Campos
- Priscila Cilene Leon Bueno de CamargoPCPriscila Cilene Leon Bueno de Camargo
- Samuel Lucas dos SantosSSSamuel Lucas dos Santos
- Ivana Teixeira de AguiarIAIvana Teixeira de Aguiar
- Juliana Patricia PiresJPJuliana Patricia Pires
- Andre Nathan CostaACAndre Nathan Costa
- Rafael Medeiros CarraroRCRafael Medeiros Carraro
- Ricardo Henrique de Oliveira Braga TeixeiraRTRicardo Henrique de Oliveira Braga Teixeira
- Paulo Manuel Pêgo-FernandesPPPaulo Manuel Pêgo-Fernandes
Open Access
- 17 December 2021
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 140 (1) , 153-159
Abstract
BACKGROUND: Lung transplantation (LTx) has been discussed as an option for treating irreversible lung fibrosis post-coronavirus disease 2019 (COVID-19), in selected cases. OBJECTIVES: To report on the initial experience and management of end-stage lung disease due to COVID-19 at a national center reference in Brazil. DESIGN AND SETTING: Cohort study conducted at a national reference center for lung transplantation. METHODS: Medical charts were reviewed regarding patients'demographics and pre-COVID-19 characteristics, post-LTx due to COVID-19. RESULTS: Between March 2020 and September 2021, there were 33 cases of LTx. During this period, we evaluated 11 cases of severe COVID-19-related acute respiratory distress syndrome (ARDS) that were potentially candidates for LTx. Among these, LTx was only indicated for three patients ( 9.1%). All of these patients were on venovenous extracorporeal membrane oxygenation ( ECMO), and the procedure that they underwent was central venoarterial ECMO. All three patients were still alive after the first 30 postoperative days. However, patient #1 and patient #2 subsequently died due to fungal sepsis on the 47th and 52nd postoperative days, respectively. Patient #3 was discharged on the 30th postoperative day. CONCLUSIONS: LTx is feasible among these complex patients. Survival over the first 30 days was 100%, and this favors surgical feasibility. Nonetheless, these were critically ill patients.Keywords
This publication has 17 references indexed in Scilit:
- Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide dataThe Lancet Respiratory Medicine, 2021
- Successful double-lung transplantation from a donor previously infected with SARS-CoV-2The Lancet Respiratory Medicine, 2021
- Setting up hospital care provision to patients with COVID-19: lessons learnt at a 2400-bed academic tertiary center in São Paulo, BrazilThe Brazilian Journal of Infectious Diseases, 2020
- Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patientThe Lancet Respiratory Medicine, 2020
- When to consider lung transplantation for COVID-19The Lancet Respiratory Medicine, 2020
- Pulmonary fibrosis secondary to COVID-19: a call to arms?The Lancet Respiratory Medicine, 2020
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- Virtually Perfect? Telemedicine for Covid-19New England Journal of Medicine, 2020
- Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosisChinese Medical Journal, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020